Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Preiss

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
JAMA|August 23, 2012
Lipid-modifying therapies and risk of pancreatitis: a meta-analysisDavid Preiss, Matti J Tikkanen, Paul Welsh, et al.
Trials|August 22, 2024
Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trialMuram El-Nayir, Rohan Wijesurendra, David Preiss, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
JAMA|June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2025
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY TrialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
Lancet (London, England)|September 13, 2016
Interpretation of the evidence for the efficacy and safety of statin therapyRory Collins, Christina Reith, Jonathan Emberson, et al.
Journal of the American Society of Nephrology : JASN|December 12, 2023
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKDKaitlin J Mayne, Natalie Staplin, David F Keane, et al.
Journal of the American College of Cardiology|March 20, 2026
African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024Bamba Gaye, Moustafa I Morsy, David Lagoro Kitara, et al.
Nature|December 26, 2019
GDF15 mediates the effects of metformin on body weight and energy balanceAnthony P Coll, Michael Chen, Pranali Taskar, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
JAMA|August 23, 2012
Lipid-modifying therapies and risk of pancreatitis: a meta-analysisDavid Preiss, Matti J Tikkanen, Paul Welsh, et al.
Trials|August 22, 2024
Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trialMuram El-Nayir, Rohan Wijesurendra, David Preiss, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
JAMA|June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2025
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY TrialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
Lancet (London, England)|September 13, 2016
Interpretation of the evidence for the efficacy and safety of statin therapyRory Collins, Christina Reith, Jonathan Emberson, et al.
Journal of the American Society of Nephrology : JASN|December 12, 2023
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKDKaitlin J Mayne, Natalie Staplin, David F Keane, et al.
Journal of the American College of Cardiology|March 20, 2026
African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024Bamba Gaye, Moustafa I Morsy, David Lagoro Kitara, et al.
Nature|December 26, 2019
GDF15 mediates the effects of metformin on body weight and energy balanceAnthony P Coll, Michael Chen, Pranali Taskar, et al.
Pageof 16